Levdobutamine
Appearance
(Redirected from LY206243)
![]() | |
Clinical data | |
---|---|
Other names | Levodobutamine; (S)-Dobutamine; LY-206243 |
Drug class | Sympathomimetic; β1-Adrenergic receptor agonist; Positive inotrope |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H23NO3 |
Molar mass | 301.386 g·mol−1 |
3D model (JSmol) | |
| |
|
Levdobutamine (INN ; developmental code name LY-206243; also known as (S)-dobutamine) is a sympathomimetic, selective β1-adrenergic receptor agonist, and positive inotrope which was never marketed.[1][2] It is the (S)-enantiomer of dobutamine.[1]
References
[edit]- ^ a b Morton IK, Hall JM (2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Netherlands. p. 164. ISBN 978-94-011-4439-1. Retrieved 27 February 2025.
- ^ Milne G, Zeman E (2017). Ashgate Handbook of Cardiovascular Agents: An International Guide to 1900 Drugs in Current Use: An International Guide to 1900 Drugs in Current Use. Routledge Revivals. Taylor & Francis. p. 228. ISBN 978-1-351-74240-5. Retrieved 27 February 2025.